Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more ... Almost six years on, we're one of the fastest growing oncology companies in the world.

Daiichi Sankyo had a day of mixed fortunes after advisers ... Quizartinib works by inhibiting FLT3 gene mutations, one of the most common genetic abnormalities in AML, associated with more ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao Manabe, DVM, PhD, will continue to serve as representative director and ...

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

Daiichi Sankyo had opposed the open offer made in 2018 after Northern TK Venture had acquired a 31% stake in Fortis. NTK had then filed a lawsuit against Daiichi Sankyo in November 2023.

Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its ...

(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...